<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001999</url>
  </required_header>
  <id_info>
    <org_study_id>079A</org_study_id>
    <secondary_id>219-90</secondary_id>
    <nct_id>NCT00001999</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Obtain Preliminary Information Regarding the Efficacy and Safety of the Combination of Immune Globulin and Ganciclovir as Compared to Ganciclovir Alone in the Treatment of Sight-Threatening CMV Retinitis in Patients With AIDS</brief_title>
  <official_title>A Pilot Study to Obtain Preliminary Information Regarding the Efficacy and Safety of the Combination of Immune Globulin and Ganciclovir as Compared to Ganciclovir Alone in the Treatment of Sight-Threatening CMV Retinitis in Patients With AIDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American National Red Cross</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate whether immune globulin and ganciclovir (DHPG) results in faster initial response&#xD;
      as compared to DHPG alone. To evaluate whether immune globulin and DHPG gives longer duration&#xD;
      of remission than DHPG alone (i.e. 16 weeks). To evaluate the toxicities of the combination&#xD;
      of DHPG and immune globulin as compared to those of DHPG alone. To evaluate if there is a&#xD;
      difference between the two groups in regard to survival, immune functions, and CMV viremia&#xD;
      and viruria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Cytomegalovirus Retinitis</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Globulin, Immune</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganciclovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  First episode of sight-threatening CMV retinitis.&#xD;
&#xD;
          -  At least one pending culture for CMV from the blood or urine prior to entry.&#xD;
&#xD;
          -  Life expectancy &gt; 6 months.&#xD;
&#xD;
          -  Karnofsky performance = or &gt; 60.&#xD;
&#xD;
          -  Ability to understand the nature of the study, to comply with study requirements, and&#xD;
             to sign informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions are excluded:&#xD;
&#xD;
          -  Known selective IGA deficiency or antibodies against IgA.&#xD;
&#xD;
          -  History of previous episodes of sight-threatening CMV retinitis.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Previous episode of sight-threatening CMV retinitis.&#xD;
&#xD;
          -  Concomitant treatment with other investigational agents except ddI or ddC.&#xD;
&#xD;
          -  Life expectancy &lt; 6 months.&#xD;
&#xD;
          -  Continued alcohol or drug abuse.&#xD;
&#xD;
          -  Known selective IgA deficiency and known to have antibodies against IgA.&#xD;
&#xD;
          -  Karnofsky performance &lt;60.&#xD;
&#xD;
        Other investigational agents except ddI or ddC.&#xD;
&#xD;
        ddI ddC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Georgetown Univ Med Ctr</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 1993</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Retinitis</keyword>
  <keyword>Gamma-Globulins</keyword>
  <keyword>Ganciclovir</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Cytomegalovirus Infections</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Immunization, Passive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Retinitis</mesh_term>
    <mesh_term>Retinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

